The Daily Toke

March 16, 2026

Virginia lawmakers have delivered a landmark recreational marijuana legalization bill to Governor Abigail Spanberger's desk, marking the latest state to transition from prohibition to regulated sales. The House voted 64-32 and the Senate 21-18 on Saturday to approve the final compromise package, following weeks of bicameral negotiations that resolved key disputes over launch dates, tax rates, and regulatory oversight. Adult-use sales will begin January 1, 2027—later than the House initially proposed but aligned with Senate preferences—with an excise tax of 6 percent, a 5.3 percent sales and use tax, and local municipalities permitted to add up to 3.5 percent. The existing Cannabis Control Authority will oversee the program rather than merging with alcohol regulators as the Senate had suggested. 💰 MONEY MOVES This framework positions Virginia to transition from its illicit market to a regulated system that will generate tax revenue while licensing operators who've met consumer protection standards. Governor Spanberger has already signaled her support for the measure, making passage into law highly likely.

Meanwhile, the political landscape on cannabis reveals sharp regional divides and mixed momentum. Tennessee lawmakers are relaunching their "Pot for Potholes" campaign to legalize recreational marijuana and dedicate tax revenue to infrastructure repair—a pragmatic pitch that frames legalization as public investment rather than pure policy change. Georgia's House passed a bipartisan bill modernizing its medical cannabis program with broad support, while Colorado sent Governor Jared Polis legislation allowing terminally ill patients to use medical cannabis in healthcare facilities. 🚀 THIS IS COOL Minnesota lawmakers approved a psilocybin therapy bill that would create a regulated program allowing adults 21 and older to access psilocybin-assisted treatment for depression, PTSD, substance use disorder, and chronic pain—with oversight from the Department of Health and a new Psychedelic Medicine Advisory Committee. Hawaii's Senate passed a bill establishing a psychedelics task force, and a new American Medical Association study found that a single psilocybin dose combined with cognitive behavioral therapy yielded significantly greater benefits for smoking cessation.

But progress isn't universal. Florida's Supreme Court effectively killed a legalization ballot initiative for 2026 by rejecting an appeal over signature collection disputes, removing recreational cannabis from voters' hands for another election cycle. 🔎 DOUBLE STANDARD WATCH The contradiction here is structural: Florida's Republican supermajority advanced conservative priorities—voter ID restrictions, anti-terrorism designations, and union restrictions—while blocking voters from deciding cannabis policy through the ballot initiative process. This pattern reflects a broader strategy in conservative-led states to make ballot initiatives harder to qualify, even when public polling suggests citizens would support them. New Hampshire's House let marijuana legalization and psilocybin therapy bills die without floor votes, despite separate proposals on those topics advancing through the legislative process. Oklahoma Governor Kevin Stitt is pushing the state legislature to send his medical cannabis rollback back to voters, claiming lawmakers support the effort—though Senate President Pro Tempore Lonnie Paxton has broken with the governor, arguing it's "really hard to completely undo" legalization after licensed operators have invested their life savings and are "trying to do this for the Oklahomans that need that product."

🤔 THINK ABOUT IT Idaho voters would likely pass medical marijuana legalization according to public polling, but lawmakers have intentionally made the ballot initiative process harder by requiring signatures to come from 18 of 35 legislative districts—effectively giving rural voters disproportionate power over what reaches the ballot, ensuring popular measures never get a public vote. A new Columbia University study found that adopting recreational cannabis laws, beyond medical-only frameworks, helps reduce illegal market size—yet states continue to debate whether legalization is worth the political capital. The Ninth Circuit Court of Appeals ruled that the Dormant Commerce Clause does not apply to state cannabis markets, sparking a circuit split that could reshape interstate cannabis commerce. Federal momentum also shifted slightly: Senator Jeff Merkley filed an amendment to a housing bill that would let cannabis industry workers qualify for federally backed mortgages by treating their income the same as other industries, acknowledging the reality that the cannabis economy now employs hundreds of thousands of Americans who currently face barriers to homeownership based on their legal employment status.

March 16, 2026

Smokable hemp products will become illegal across Texas in less than three weeks, marking one of the most significant reversals for the state's booming cannabis industry. The Texas Department of State Health Services finalized new regulations on March 6 that redefine how THC content is measured in hemp products—shifting from testing only delta-9 THC (the primary psychoactive compound) to measuring total THC content, which includes THCA, a non-psychoactive cannabinoid that converts to delta-9 when heated at roughly an 88% conversion rate. The rules take effect March 31, effectively ending the legal sale of smokable hemp flower and extracts, even though hemp-derived drinks and edibles will remain available. Gov. Greg Abbott vetted a full hemp ban last June, but instead issued an executive order demanding stricter regulations, which DSHS ultimately delivered through this testing standard change.

The economic fallout is immediate and severe. 💰 MONEY MOVES The Texas hemp industry generates between $10-12 billion annually and employs over 50,000 people, according to Mark Bordas, executive director of the Texas Hemp Business Council. Hemp store operators report that smokable hemp represents 60-70% of their sales, meaning the ban will effectively shut down businesses overnight. One anonymous shop owner told reporters he'll have to close entirely. Nicholas Mortillaro, a hemp store operator, predicted statewide revenue declines of 60-70% within three weeks. The new regulations also impose annual licensing fees—$5,000 for retailers and $10,000 for manufacturers—designed to fund state regulatory costs but adding another burden to an already-struggling industry.

The pattern isn't isolated to Texas. Ohio CBD stores and breweries are bracing for a state hemp ban. South Carolina lawmakers are debating whether to ban intoxicating hemp products entirely. And federal lawmakers are considering sweeping hemp restrictions that could affect every state's THC industry, estimated at $1 billion-plus nationally. Heather Fazio, director of the Texas Cannabis Policy Center, warned that pushing consumers away from tested, legal products will hand the market to illicit operators—meaning untested products will replace regulated ones. This mirrors a documented pattern: prohibition-era policies often increase underground market activity rather than eliminate consumption.

🤔 THINK ABOUT IT The stated goal of these bans is consumer protection and child safety, yet alcohol—which kills approximately 95,000 Americans annually and is the #1 drug-related killer of teenagers—remains legal and heavily marketed in every state. Cannabis has zero recorded overdose deaths in human history. So when policymakers restrict a zero-death product while leaving a 95,000-death product freely available, what problem are they actually solving?

The Texas industry is preparing legal challenges to the new rules. Some cannabis policy experts argue the total THC testing standard is scientifically unreasonable—THCA doesn't cause intoxication until heated, yet will be counted toward the 0.3% legal threshold. The contradiction between the ban's stated protective goals and its likely outcome—pushing consumers toward unregulated, untested products—has forced business owners into an impossible position. In less than three weeks, thousands of Texans will lose jobs, and a $10-12 billion industry will shrink dramatically, all while policymakers argue they're protecting public health.

March 16, 2026

Research published this week reveals cannabis compounds are advancing on multiple therapeutic fronts, from cancer cells to chronic pain, while new data on THC's memory effects raises questions about dosing safety and real-world cognitive impacts.

🚀 THIS IS COOL Cannabidiol (CBD) showed comparable binding strength to established cancer drugs across four key breast cancer pathways in a computational study from Amity University and Assam Down Town University. The research, published in Current Drug Discovery Technologies, found CBD interacted effectively with CDK6 (cell cycle regulation), BCL2 (apoptosis resistance), MMP2 (tumor spread), and VEGFR2 (blood vessel formation)—matching or exceeding reference compounds like palbociclib and axitinib. The implications matter because breast cancer progression involves multiple overlapping biological processes, and a single compound targeting several simultaneously could offer broader therapeutic coverage. Researchers emphasized these results are computational models requiring laboratory and clinical validation, but the timing is significant: in the past two months alone, studies have shown CBD selectively impairing HER2-positive breast cancer cells, an exosome-based oral CBD formulation slowing aggressive triple-negative breast cancer while altering over 1,000 cancer-related genes, and a CBC-CBD combination shrinking drug-resistant tumors in lab and animal models.

🚀 THIS IS COOL A separate line of research from Hebrew University of Jerusalem identified a mechanism by which CBD and CBG reduce liver fat and improve metabolic health—addressing metabolic dysfunction-associated steatotic liver disease (MASLD), which affects approximately one-third of the global adult population. Lead researcher Joseph Tam's team found the compounds trigger a "metabolic remodeling" process, increasing phosphocreatine and cathepsin enzymes that enhance the liver's energy resilience and ability to clear toxins. The findings were published in the British Journal of Pharmacology and represent a new angle on cannabis therapeutics: instead of targeting cancer or pain receptors directly, these compounds appear to rewrite how an organ manages energy and cellular cleanup.

🚀 THIS IS COOL In a real-world analysis of 484 older adults (age 65+) from Germany's Pain e-Registry, CBD-dominant full-spectrum extracts significantly outperformed pure THC across every major outcome category. Patients on CBD-dominant treatments reported greater pain relief, better sleep, improved daily functioning, and higher quality of life—while experiencing far fewer side effects. The CBD group reported 104 adverse reactions versus 342 in the THC group; only 15.5 percent experienced side effects compared to 35.7 percent in the THC cohort. Treatment discontinuation due to adverse effects dropped from 19.2 percent (THC) to 5.6 percent (CBD-dominant). Eighty-five point seven percent of CBD patients met the study's primary endpoint—meaningful pain improvement without stopping treatment due to side effects—versus just 21.9 percent of pure THC patients. Additional good news came from the University of Otago, Wellington, where medicinal cannabis reduced endometriosis and pelvic pain while improving sleep and lowering anxiety, and from Italy, where a non-psychotropic cannabis essential oil reduced pain, improved mobility, and eased anxiety and depression in a multiple sclerosis animal model.

But not all cannabis news is straightforward. Washington State University researchers publishing in the Journal of Psychopharmacology found that THC doesn't simply blur memory—it actively creates false memories. In a double-blind study of 120 regular cannabis users, participants who consumed THC were significantly more likely to recall words never shown to them and struggled with prospective memory tasks (remembering to do something later), source memory (recalling where information came from), and temporal ordering. 🤔 THINK ABOUT IT The research showed no meaningful difference between 20 milligrams and 40 milligrams of THC, suggesting even moderate doses substantially disrupt memory formation across multiple systems. This finding complicates the emerging narrative around cannabis as a medical tool: while CBD-dominant formulations show strong therapeutic potential with minimal side effects, THC's cognitive footprint appears broader and more pronounced than previously documented.

💰 MONEY MOVES Medicare is preparing a proposal, expected to launch as early as April 2026, that would provide beneficiaries up to $500 annually to purchase CBD products—a move supporters argue could reduce reliance on opioids and benzodiazepines while expanding access to alternative pain and anxiety treatments. Separately, delta-8 THC products have spiked in popularity (gummies, vapes, pre-rolls, tinctures), though Medical Xpress reports inconsistent labeling and higher-than-advertised doses in many commercial products. A Columbia University study also found that recreational cannabis legalization—beyond medical-only frameworks—appears to displace illegal cannabis markets in U.S. states, suggesting regulatory frameworks may reshape market dynamics more effectively than prohibition alone.

The science briefing this week underscores an emerging pattern: non-intoxicating or CBD-dominant cannabis compounds are showing therapeutic promise across cancer, liver disease, pain, and neurological conditions, while pure THC carries cognitive tradeoffs worth monitoring. The federal policy conversation, currently stalled with cannabis remaining Schedule I despite zero recorded overdose deaths in human history, increasingly appears disconnected from the clinical evidence accumulating in peer-reviewed journals.

March 16, 2026

Texas regulators have finalized a ban on smokable cannabis products effective March 31, 2026—a move that will effectively eliminate roughly 50 percent of the state's legal hemp market and push thousands of products underground. The Texas Department of State Health Services adopted the new rules last week, fundamentally changing how the state measures THC potency. Instead of testing only delta-9 THC (the primary psychoactive compound), products will now be evaluated for "total THC," which includes THCA—a non-psychoactive cannabinoid that converts to delta-9 when heated. The shift closes a loophole that hemp retailers have relied on since a 2019 federal definitional change allowed cannabis products with less than 0.3 percent delta-9 THC to be sold legally. Under the new standard, virtually all smokable hemp flower will become non-compliant. 💰 MONEY MOVES Retail hemp businesses will face annual licensing fees jumping from $150 to $5,000 per location, while manufacturers must pay $10,000 annually—fees that are lower than initially proposed ($20,000 for retailers, $25,000 for manufacturers) but still substantial enough to force closures across the state's 8,000 registered hemp retailers. Industry executives are bracing for catastrophic impacts. Mark Bordas, executive director of the Texas Hemp Business Council, says the regulations will shutter stores employing over 50,000 Texans and disrupt a $10–12 billion annual industry. Hemp store operator Nicholas Mortillaro estimates his business will see 60–70 percent revenue declines within three weeks. One shop owner, speaking anonymously due to fears of retaliation, said the rules "will effectively shut down our businesses overnight."

The regulatory crackdown comes despite Governor Greg Abbott's June 2025 veto of Senate Bill 3, which would have banned hemp-derived THC products outright. Instead of prohibition, Abbott issued an executive order directing state agencies to regulate the market more strictly. The Legislature itself had failed to reach consensus on how to handle hemp products, but Abbott's order to DSHS triggered the new testing requirements and fee structures. 🤔 THINK ABOUT IT Alcohol kills approximately 95,000 Americans per year. Prescription opioids kill 16,000 annually. Cannabis has zero recorded overdose deaths in human history. Yet Texas regulators are moving to eliminate a zero-death product while the state continues to distribute alcoholic beverages at restaurants, bars, and stores everywhere.

Importantly, edibles and infused drinks will remain legal under the new rules—a carve-out that suggests the regulations are less about public health and more about targeting a specific product category. Heather Fazio, director of the Texas Cannabis Policy Center, calls the total THC testing standard "unreasonably restrictive," estimating it will hand 50 percent of the legal market to illicit operators and make consumers seek untested products from unregulated sources. The hemp industry received some minor victories: licensing fees were reduced from the initially proposed amounts, and the DSHS acknowledged 21 of dozens of public comments urging revisions. Yet the agency rejected requests to exclude THCA from the total THC calculation or to create exceptions for smokable products.

The ban coincides with an alarming increase in law enforcement raids on hemp businesses. Since August 2024, more than 15 businesses across Texas have been raided by local police and the DEA, with law enforcement seizing products, cash, vehicles, and assets that retailers have not recovered—even as most have faced no criminal charges. Dallas attorney Chelsie Spencer, who specializes in hemp compliance, recalls one client being raided as if he were "a major narcotics dealer," with officers taking children's cellphones, computers, vehicles, and all cash.

The medical cannabis program, by contrast, continues expanding steadily. Texas officials have approved nine new medical marijuana licenses with three more expected before April 1, showing that when products move into medical channels with clinical oversight, the state's regulatory appetite shifts dramatically. 🚀 THIS IS COOL The medical program represents "steady progress" in expanding patient access, suggesting that the apparatus for safe, regulated cannabis commerce already exists in Texas—but only for patients, not adults. All of this raises a fundamental question about regulatory consistency: Texas allows edible and infused hemp products to remain legal while banning smokables, permits medical cannabis expansion while restricting adult-use hemp, and increases enforcement pressure while simultaneously pushing consumers toward unregulated alternatives. These aren't inherent contradictions—they're policy choices. And those choices have real economic consequences for the tens of thousands of Texans employed in the legal hemp industry.